Using this methodology, we revealed that A1AT, which is approved by the FDA for the treatment of A1AT deficiency, can efficiently inhibit TMPRSS2. The gene discussed is TMPRSS2; the disease is hyperinsulinemic hypoglycemia, familial, 4.